SOURCE: AtheroGenics

August 29, 2007 09:21 ET

New Data on AtheroGenics AGI-1067 Accepted for Presentation at the European Society of Cardiology Congress 2007

ATLANTA, GA--(Marketwire - August 29, 2007) - AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that new scientific data of its oral antidiabetic agent AGI-1067 has been accepted for an oral presentation in a Hotline & Clinical Update session at the upcoming European Society of Cardiology (ESC) Congress 2007 in Vienna, Austria.

The presentation is titled, "The effect of the novel anti-oxidant AGI-1067 (succinobucol) on glycemic control, new onset diabetes and clinical events in patients with a recent acute coronary syndrome: the Aggressive Reduction of Inflammation Stops Events study (ARISE)." It will be presented on Wednesday, September 5, 2007, by Marc Pfeffer, M.D., Ph.D., Dzau Professor of Medicine, Harvard Medical School; Senior Physician in Cardiology at Brigham and Women's Hospital and co-principal investigator of the ARISE clinical trial.

Additional information regarding the ESC Congress 2007 can be accessed at http://www.escardio.org.

About AGI-1067

AGI-1067 has demonstrated efficacy in over 2,200 diabetic subjects showing improvements in glycemic control. This effect with AGI-1067 has been confirmed in other clinical and preclinical studies. Oxidative stress and inflammation have been demonstrated to play a central role in the pathogenesis of insulin resistance and diabetes. AGI-1067 is an anti-inflammatory antioxidant agent that works by inhibiting signaling pathways that are activated in response to oxidative stress and pro-inflammatory stimuli.

AGI-1067 has been evaluated in numerous pre-clinical and clinical studies, including a recent cardiovascular clinical outcomes study comprised of 6,144 subjects followed for up to three years. In that study, AGI-1067 achieved significant results in important pre-specified diabetes endpoints, demonstrating an improvement in glycemic control in patients with diabetes already being managed by conventional therapies. In addition, the number of study subjects who developed diabetes for the first time was reduced by more than 60 percent.

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease (atherosclerosis). The Company's lead compound, AGI-1067, is being studied in a Phase III clinical trial called ANDES (AGI-1067 as a Novel Anti-Diabetic Agent Evaluation Study) as an oral therapy for the treatment of diabetes. In addition, the Company has a development program studying AGI-1096, an oral agent in Phase I that is being developed for the prevention of organ transplant rejection in collaboration with Astellas. For more information about AtheroGenics, please visit http://www.atherogenics.com.

Disclosure Regarding Forward-Looking Statements

Statements contained in this press release that relate to events or developments that we expect or anticipate will occur in the future are deemed to be forward-looking statements, and can be identified by words such as "believes," "intends," "expects" and similar expressions. AtheroGenics cautions investors not to place undue reliance on the forward-looking statements contained in this release. These and other such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performances to differ materially from those referred to in such statements. Additional information relating to the safety, efficacy or tolerability of AGI-1067, may be discovered upon further analysis of trial data. The Food and Drug Administration might not allow us to conduct further studies of the efficacy of AGI-1067 for the same or new endpoints, and, to the extent approved, additional clinical trial work may take a significant period of time to complete or require significant additional resources to complete. There may be significant costs incurred by AtheroGenics as a result of AstraZeneca's decision to terminate the AGI-1067 collaboration and license agreement. We cannot ensure that AGI-1067 will ever be approved or be proven safe and effective for use in humans. These and other risks are discussed in AtheroGenics' Securities and Exchange Commission filings, including, but not limited to, the risks discussed in AtheroGenics' Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 and are specifically incorporated by reference into this press release. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact Information

  • AtheroGenics, Inc.
    Donna Glasky
    Corporate Communications
    678-336-2517
    Email Contact

    Media Inquiries
    Jayme Maniatis
    Schwartz Communications, Inc.
    781-684-0770
    Email Contact

    Investor Inquiries
    Lilian Stern
    Stern Investor Relations, Inc.
    212-362-1200
    Email Contact